The Role of Oncolytic Viruses in the Treatment of Melanoma

被引：34
作者：
Bayan, Claire-Audrey Y. [1 ]
Lopez, Adriana T. [1 ]
Gartrell, Robyn D. [2 ]
Komatsubara, Kimberly M. [2 ]
Bogardus, Margaret [1 ]
Rao, Nisha [2 ]
Chen, Cynthia [1 ]
Hart, Thomas D. [3 ]
Enzler, Thomas [2 ]
Rizk, Emanuelle M. [2 ]
Pradhan, Jaya Sarin [4 ]
Marks, Douglas K. [2 ]
Geskin, Larisa J. [5 ]
Saenger, Yvonne M. [2 ]
机构：
[1] Columbia Univ, Med Ctr, New York, NY 10032 USA
[2] Columbia Univ, Med Ctr, Dept Med, Div Hematol Oncol, 161 Ft Washington Ave, New York, NY 10032 USA
[3] Columbia Univ, Columbia Coll, New York, NY 10027 USA
[4] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA
[5] Columbia Univ, Med Ctr, Dept Dermatol, New York, NY 10032 USA
来源：
CURRENT ONCOLOGY REPORTS | 2018年 / 20卷 / 10期
关键词：
Oncolytic virus; Oncolytic viral therapy; Melanoma; Immunotherapy; Talimogene laherparepvec (T-VEC); Tumor microenvironment; Biosafety; Combination therapy; HERPES-SIMPLEX-VIRUS; NEWCASTLE-DISEASE VIRUS; PHASE-I TRIAL; COSTIMULATORY MOLECULES; TALIMOGENE LAHERPAREPVEC; MALIGNANT-MELANOMA; MEASLES-VIRUS; TUMOR; EXPRESSION; TYPE-1;
D O I：
10.1007/s11912-018-0729-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose of Review Oncolytic virotherapy is a new approach to the treatment of cancer and its success in the treatment of melanoma represents a breakthrough in cancer therapeutics. This paper provides a review of the current literature on the use of oncolytic viruses (OVs) in the treatment of melanoma. Recent Findings Talimogene laherparepvec (T-VEC) is the first OV approved for the treatment of melanoma and presents new challenges as it enters the clinical setting. Several other OVs are at various stages of clinical and pre-clinical development for the treatment of melanoma. Reports from phase Ib-III clinical trials combining T-VEC with checkpoint blockade are encouraging and demonstrate potential added benefit of combination immunotherapy. Summary OVs have recently emerged as a standard treatment option for patients with advanced melanoma. Several OVs and therapeutic combinations are in development. Immunooncolytic virotherapy combined with immune checkpoint inhibitors is promising for the treatment of advanced melanoma.
引用
收藏
页数：14
相关论文
共 85 条
  • [1] Intranodal Immunization With a Vaccinia Virus Encoding Multiple Antigenic Epitopes and Costimulatory Molecules in Metastatic Melanoma
    Adamina, Michel
    Rosenthal, Rachel
    Weber, Walter P.
    Frey, Daniel M.
    Viehl, Carsten T.
    Bolli, Martin
    Huegli, Rolf W.
    Jacob, Augustinus L.
    Heberer, Michael
    Oertli, Daniel
    Marti, Walter
    Spagnoli, Giulio C.
    Zajac, Paul
    [J]. MOLECULAR THERAPY, 2010, 18 (03) : 651 - 659
  • [2] Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports
    Alberts, Peteris
    Olmane, Evija
    Brokane, Linda
    Krastina, Zanda
    Romanovska, Mara
    Kupcs, Karlis
    Isajevs, Sergejs
    Proboka, Guna
    Erdmanis, Romualds
    Nazarovs, Jurijs
    Venskus, Dite
    [J]. APMIS, 2016, 124 (10) : 896 - 904
  • [3] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
    Andtbacka, Robert H. I.
    Kaufman, Howard L.
    Collichio, Frances
    Amatruda, Thomas
    Senzer, Neil
    Chesney, Jason
    Delman, Keith A.
    Spitler, Lynn E.
    Puzanov, Igor
    Agarwala, Sanjiv S.
    Milhem, Mohammed
    Cranmer, Lee
    Curti, Brendan
    Lewis, Karl
    Ross, Merrick
    Guthrie, Troy
    Linette, Gerald P.
    Daniels, Gregory A.
    Harrington, Kevin
    Middleton, Mark R.
    Miller, Wilson H., Jr.
    Zager, Jonathan S.
    Ye, Yining
    Yao, Bin
    Li, Ai
    Doleman, Susan
    VanderWalde, Ari
    Gansert, Jennifer
    Coffin, Robert S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) : 2780 - U98
  • [4] Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.
    Andtbacka, Robert Hans Ingemar
    Ross, Merrick I.
    Agarwala, Sanjiv S.
    Taylor, Matthew H.
    Vetto, John T.
    Neves, Rogerio Izar
    Daud, Adil
    Khong, Hung T.
    Ungerleider, Richard S.
    Tanaka, Maki
    Grossmann, Kenneth F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] [Anonymous], 2017, NEOADJUVANT TRIAL NI
  • [6] [Anonymous], 2010, STUDY INTRATUMORAL C
  • [7] [Anonymous], 2015, J IMMUNOTHER CANC S2, V3, pP180
  • [8] [Anonymous], 2012, EFFICACY SAFETY INTR
  • [9] [Anonymous], J CLIN ONCOL S
  • [10] YVEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection
    Arulanandam, Rozanne
    Batenchuk, Cory
    Angarita, Fernando A.
    Ottolino-Perry, Kathryn
    Cousineau, Sophie
    Mottashed, Amelia
    Burgess, Emma
    Falls, Theresa J.
    De Silva, Naomi
    Tsang, Jovian
    Howe, Grant A.
    Bourgeois-Daigneault, Marie-Claude
    Conrad, David P.
    Daneshmand, Manijeh
    Breitbach, Caroline J.
    Kim, David H.
    Raptis, Leda
    Sad, Subash
    Atkins, Harold
    Huh, Michael S.
    Diallo, Jean-Simon
    Lichty, Brian D.
    Ilkow, Carolina S.
    Le Boeuf, Fabrice
    Addison, Christina L.
    McCart, J. Andrea
    Bell, John C.
    [J]. CANCER CELL, 2015, 28 (02) : 210 - 224
123456789